Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.
作者信息
Michallet Anne-Sophie, Guillermin Yann, Deau Benedicte, Lebras Laure, Harel Stephanie, Amorin Sandy, Reynes Claire, Salles Gilles, Subtil Fabien, Brice Pauline
机构信息
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Department of Hematology, Pierre Bénite, France
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Department of Hematology, Pierre Bénite, France.
出版信息
Haematologica. 2015 Jul;100(7):e269-71. doi: 10.3324/haematol.2015.124784. Epub 2015 Apr 3.
Abstract
摘要
相似文献
1
Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.吉西他滨、长春瑞滨、聚乙二醇脂质体阿霉素和布伦妥昔单抗序贯联合作为复发或难治性霍奇金淋巴瘤移植前的桥接方案。
Haematologica. 2015 Jul;100(7):e269-71. doi: 10.3324/haematol.2015.124784. Epub 2015 Apr 3.
2
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.帕博利珠单抗联合吉西他滨、长春瑞滨和脂质体多柔比星作为二线治疗复发或难治性经典型霍奇金淋巴瘤的 II 期临床试验。
J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25.
3
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.吉西他滨、长春瑞滨和聚乙二醇化脂质体阿霉素（GVD），复发霍奇金淋巴瘤的挽救方案：癌症和白血病研究组B（CALGB）59804。
Ann Oncol. 2007 Jun;18(6):1071-9. doi: 10.1093/annonc/mdm090. Epub 2007 Apr 10.
4
Salvage therapy with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin for relapsed or refractory pediatric Hodgkin lymphoma. Results of a retrospective series of four children.吉西他滨、长春瑞滨和聚乙二醇化脂质体阿霉素用于复发或难治性儿童霍奇金淋巴瘤的挽救治疗。4例儿童回顾性系列研究结果
Ann Hematol. 2015 Aug;94(8):1401-6. doi: 10.1007/s00277-015-2362-7. Epub 2015 Apr 12.
5
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.贝林妥欧单抗联合吉西他滨治疗儿童和青年复发或难治性霍奇金淋巴瘤患者（AHOD1221）：一项儿童肿瘤学组多中心单臂 1-2 期试验。
Lancet Oncol. 2018 Sep;19(9):1229-1238. doi: 10.1016/S1470-2045(18)30426-1. Epub 2018 Aug 16.
6
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.SGN-30、吉西他滨、长春瑞滨和脂质体多柔比星联合治疗霍奇金淋巴瘤患者出现严重肺部毒性与 FcγRIIIa-158 V/F 多态性相关。
Ann Oncol. 2010 Nov;21(11):2246-2254. doi: 10.1093/annonc/mdq211. Epub 2010 Apr 27.
7
Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.吉西他滨、长春瑞滨、脂质体多柔比星（GVD）14 天方案作为挽救方案治疗既往大量治疗的霍奇金淋巴瘤和侵袭性非霍奇金淋巴瘤患者具有良好的长期疗效。
Med Oncol. 2013 Mar;30(1):350. doi: 10.1007/s12032-012-0350-5. Epub 2013 Jan 18.
8
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.复发/难治性霍奇金淋巴瘤自体移植前，以本妥昔单抗作为二线治疗的多中心II期试验结果。
Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-2140. doi: 10.1016/j.bbmt.2015.07.018. Epub 2015 Jul 26.
9
Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.PD-1 抑制剂联合 GVD（吉西他滨、长春瑞滨、脂质体多柔比星）与 GVD 方案作为复发/难治性经典霍奇金淋巴瘤二线治疗的比较。
Br J Haematol. 2022 Jan;196(1):127-135. doi: 10.1111/bjh.17849. Epub 2021 Oct 7.
10
Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.吉西他滨联合长春瑞滨方案在 ASCT 前用于复发或难治性霍奇金淋巴瘤的挽救和动员治疗是有效的。
Ann Hematol. 2011 Jun;90(6):685-91. doi: 10.1007/s00277-010-1113-z. Epub 2010 Nov 12.
引用本文的文献
1
Atypical location of primary cardiac lymphoma in the left heart with atypical clinical presentation: A case report and literature review.原发性心脏淋巴瘤位于左心的非典型部位并伴有非典型临床表现：一例病例报告及文献综述
Front Surg. 2023 Jan 16;9:1036519. doi: 10.3389/fsurg.2022.1036519. eCollection 2022.
2
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study.难治性或复发性霍奇金淋巴瘤患者自体干细胞移植后接受维布妥昔单抗维持治疗的结局：一项法国多中心观察性队列研究
Haematologica. 2022 Jul 1;107(7):1681-1686. doi: 10.3324/haematol.2021.279564.
3
Salvage Therapy for Hodgkin's Lymphoma: A Review of Current Regimens and Outcomes.霍奇金淋巴瘤的挽救治疗：当前治疗方案及结果综述
J Blood Med. 2020 Oct 27;11:389-403. doi: 10.2147/JBM.S250581. eCollection 2020.
4
[Interstitial pneumonia in patients with diffuse large B-cell lymphoma receiving RCHOP and RCDOP regimens].接受RCHOP和RCDOP方案治疗的弥漫性大B细胞淋巴瘤患者的间质性肺炎
Zhonghua Xue Ye Xue Za Zhi. 2019 Dec 14;40(12):1015-1020. doi: 10.3760/cma.j.issn.0253-2727.2019.12.008.
5
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.本妥昔单抗联合地塞米松、大剂量阿糖胞苷和顺铂作为复发/难治性经典型霍奇金淋巴瘤挽救治疗的Ⅰ期剂量递增研究：HOVON/LLPC移植BRAVE研究
Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31.
6
Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review.维布妥昔单抗治疗霍奇金淋巴瘤和间变性大细胞淋巴瘤：一项基于证据的综述。
Onco Targets Ther. 2018 Aug 6;11:4583-4590. doi: 10.2147/OTT.S141053. eCollection 2018.
7
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.贝林妥欧单抗联合吉西他滨治疗儿童和青年复发或难治性霍奇金淋巴瘤患者（AHOD1221）：一项儿童肿瘤学组多中心单臂 1-2 期试验。
Lancet Oncol. 2018 Sep;19(9):1229-1238. doi: 10.1016/S1470-2045(18)30426-1. Epub 2018 Aug 16.
8
[Efficacy of RCDOP regimen in the treatment of patients with diffuse large B-cell lymphoma].RCDOP方案治疗弥漫性大B细胞淋巴瘤患者的疗效
Zhonghua Xue Ye Xue Za Zhi. 2018 Jun 14;39(6):485-490. doi: 10.3760/cma.j.issn.0253-2727.2018.06.010.
9
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.维布妥昔单抗治疗复发/难治性霍奇金淋巴瘤。希腊的经验。
Hematol Oncol. 2018 Feb;36(1):174-181. doi: 10.1002/hon.2383. Epub 2017 Feb 20.
10
Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.使用维布妥昔单抗靶向CD30治疗霍奇金淋巴瘤
Cancer J. 2016 Jan-Feb;22(1):23-6. doi: 10.1097/PPO.0000000000000168.
本文引用的文献
1
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.PET 适应序贯挽救治疗，采用 Brentuximab Vedotin 继以增强异环磷酰胺、卡铂和依托泊苷，用于复发和难治性霍奇金淋巴瘤患者：一项非随机、开放标签、单中心、2 期研究。
Lancet Oncol. 2015 Mar;16(3):284-92. doi: 10.1016/S1470-2045(15)70013-6. Epub 2015 Feb 13.
2
Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.本妥昔单抗治疗多次复发的霍奇金淋巴瘤和间变性大细胞淋巴瘤：一项纳入45例患者的单中心研究
Br J Haematol. 2014 Jul;166(2):306-8. doi: 10.1111/bjh.12849. Epub 2014 Mar 27.
3
Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.苯达莫司汀治疗复发性霍奇金淋巴瘤患者的疗效和安全性。
Br J Haematol. 2013 Jan;160(2):207-15. doi: 10.1111/bjh.12120. Epub 2012 Nov 20.
4
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.一项评估 Brentuximab vedotin 治疗复发或难治性霍奇金淋巴瘤患者的关键性 II 期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.
5
How I treat relapsed and refractory Hodgkin lymphoma.我如何治疗复发和难治性霍奇金淋巴瘤。
Blood. 2011 Apr 21;117(16):4208-17. doi: 10.1182/blood-2010-09-288373. Epub 2011 Jan 24.
6
Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.采用单倍体或串联自体干细胞移植对首次复发/难治性霍奇金淋巴瘤进行风险适应性挽救治疗：GELA/SFGM研究组前瞻性多中心H96试验结果
J Clin Oncol. 2008 Dec 20;26(36):5980-7. doi: 10.1200/JCO.2007.15.5887. Epub 2008 Nov 17.
7
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.苯达莫司汀用于利妥昔单抗难治性惰性和转化型非霍奇金淋巴瘤患者：一项II期多中心单药研究的结果
J Clin Oncol. 2008 Jan 10;26(2):204-10. doi: 10.1200/JCO.2007.12.5070.
8
Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.通过抗CD30单克隆抗体SGN - 30发出的信号使霍奇金病细胞对传统化疗药物敏感。
Leukemia. 2005 Sep;19(9):1648-55. doi: 10.1038/sj.leu.2403884.
9
Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines.人抗CD30抗体5F11与细胞抑制药物联合使用可增强其对霍奇金淋巴瘤和间变性大细胞淋巴瘤细胞系的抗肿瘤活性。
J Immunother. 2004 Sep-Oct;27(5):347-53. doi: 10.1097/00002371-200409000-00003.
10
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.时间强化地塞米松/顺铂/阿糖胞苷：复发难治性霍奇金淋巴瘤患者的一种低毒性有效挽救疗法。
Ann Oncol. 2002 Oct;13(10):1628-35. doi: 10.1093/annonc/mdf221.
Zotero 插件